DE60128911D1 - Verwendung von l-threo-methylphenidat zur herstellung eines medikamentes zur behandlung von psychischen erkrankungen - Google Patents

Verwendung von l-threo-methylphenidat zur herstellung eines medikamentes zur behandlung von psychischen erkrankungen

Info

Publication number
DE60128911D1
DE60128911D1 DE60128911T DE60128911T DE60128911D1 DE 60128911 D1 DE60128911 D1 DE 60128911D1 DE 60128911 T DE60128911 T DE 60128911T DE 60128911 T DE60128911 T DE 60128911T DE 60128911 D1 DE60128911 D1 DE 60128911D1
Authority
DE
Germany
Prior art keywords
medicament
manufacture
treatment
threo methylphenidate
psychic diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60128911T
Other languages
English (en)
Other versions
DE60128911T2 (de
Inventor
Ross Baldessarini
Alexander Campbell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mclean Hospital Corp
Original Assignee
Mclean Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mclean Hospital Corp filed Critical Mclean Hospital Corp
Application granted granted Critical
Publication of DE60128911D1 publication Critical patent/DE60128911D1/de
Publication of DE60128911T2 publication Critical patent/DE60128911T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60128911T 2000-04-12 2001-04-11 Verwendung von l-threo-methylphenidat zur herstellung eines medikamentes zur behandlung von psychischen erkrankungen Expired - Fee Related DE60128911T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/547,767 US6221883B1 (en) 2000-04-12 2000-04-12 Method of dopamine inhibition using l-threo-methylphenidate
US547767 2000-04-12
PCT/US2001/005826 WO2001078729A1 (en) 2000-04-12 2001-04-11 Method of dopamine inhibition using l-threo-methylphenidate

Publications (2)

Publication Number Publication Date
DE60128911D1 true DE60128911D1 (de) 2007-07-26
DE60128911T2 DE60128911T2 (de) 2008-02-21

Family

ID=24186038

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60128911T Expired - Fee Related DE60128911T2 (de) 2000-04-12 2001-04-11 Verwendung von l-threo-methylphenidat zur herstellung eines medikamentes zur behandlung von psychischen erkrankungen

Country Status (5)

Country Link
US (1) US6221883B1 (de)
EP (1) EP1292305B1 (de)
AU (1) AU2001252884A1 (de)
DE (1) DE60128911T2 (de)
WO (1) WO2001078729A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US9098297B2 (en) * 1997-05-08 2015-08-04 Nvidia Corporation Hardware accelerator for an object-oriented programming language
US6962997B1 (en) * 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
US6480205B1 (en) 1998-07-22 2002-11-12 Nvidia Corporation Method and apparatus for occlusion culling in graphics systems
US6844880B1 (en) 1999-12-06 2005-01-18 Nvidia Corporation System, method and computer program product for an improved programmable vertex processing model with instruction set
US7209140B1 (en) 1999-12-06 2007-04-24 Nvidia Corporation System, method and article of manufacture for a programmable vertex processing model with instruction set
WO2002017919A2 (en) * 2000-08-28 2002-03-07 Sention, Inc. Use of threo-methylphenidate compounds to enhance memory
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
JP2008523097A (ja) * 2004-12-09 2008-07-03 セルジーン・コーポレーション Ｄ−トレオメチルフェニデートを用いた治療

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514451D0 (en) 1995-07-14 1995-09-13 Chiroscience Ltd Sustained-release formulation
US5908850A (en) 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
EP0948484A1 (de) * 1996-12-13 1999-10-13 Medeva Europe Limited Herstellung von enantiomer angereichertem threo-methylphenidate

Also Published As

Publication number Publication date
EP1292305A1 (de) 2003-03-19
EP1292305A4 (de) 2004-04-07
WO2001078729A1 (en) 2001-10-25
AU2001252884A1 (en) 2001-10-30
EP1292305B1 (de) 2007-06-13
DE60128911T2 (de) 2008-02-21
US6221883B1 (en) 2001-04-24

Similar Documents

Publication Publication Date Title
ATE248599T1 (de) Verwendung von xenon zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von neurovergiftungen
DE60320007D1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
ATE417606T1 (de) Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
DE60142473D1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
ATE271038T1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
DE60029033D1 (de) Verfahren zur Behandlung von Tissuepapier
ATE292134T1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE69824576D1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
DE69934813D1 (de) Verwendung von gaba analogen zur herstellung eines arzneimittels zur behandlung von manie und bipolaren erkrankungen
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE60027209D1 (de) Arzneimittel enthaltend hydroxyapatite zur behandlung von knochengewebserkrankungen
DE602004029465D1 (de) Externes Präparat zur Behandlung von Fusspilz
DE60128911D1 (de) Verwendung von l-threo-methylphenidat zur herstellung eines medikamentes zur behandlung von psychischen erkrankungen
DE50201780D1 (de) Halogensubstituierte aminodicarbonsäurederivate als arzneimittel zur behandlung von herz-kreislauf-erkrankungen
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
DE69910202D1 (de) EGR-1 zur Herstellung eines Medikamentes zur Behandlung von Wunden
DE59914712D1 (de) Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
DE60318327D1 (de) Verwendung von resveratrol zur herstellung eines arzneimittels zur behandlung von grippe
ATE314850T1 (de) Verwendung einer pharmazeutische zusammensetzung enthaltend desoxypeganin zur behandlung der nikotinabhängigkeit
ATE289196T1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE69901243D1 (de) Artikulator zur herstellung von zahnärztlichen prothesen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee